Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy.


Journal

The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002

Informations de publication

Date de publication:
05 2021
Historique:
received: 06 04 2020
revised: 07 08 2020
accepted: 17 08 2020
pubmed: 12 10 2020
medline: 25 9 2021
entrez: 11 10 2020
Statut: ppublish

Résumé

Despite the efficacy of allergen-specific immunotherapy (AIT), the role of trained immunity and tolerance in this process has not been elucidated. Here, we have performed a comprehensive longitudinal analysis of the systemic innate immune cell repertoire during the course of AIT. Patients with allergy received standard preseasonal subcutaneous AIT with allergoids to birch and/or grass. Healthy controls were monitored without any intervention. Flow cytometry of innate lymphoid cell (ILC), natural killer cell, monocyte cell, and dendritic cell (DC) subsets was performed at baseline, 3 months (birch season), 6 months (grass seasons), and 12 months after the therapy in patients or at similar seasonal time points in controls. Additional analyses were performed in the third-year birch and grass season. We observed a durable decrease in group 2 ILCs and an increase of group 1 ILCs after AIT, with dynamic changes in their composition. We found that an expansion of CD127 AIT induces changes in the composition and heterogeneity of circulating innate immune cells and brings them to the level observed in healthy individuals. Monitoring of ILCs, monocytes, and DCs during AIT might serve as a novel biomarker strategy.

Sections du résumé

BACKGROUND
Despite the efficacy of allergen-specific immunotherapy (AIT), the role of trained immunity and tolerance in this process has not been elucidated.
OBJECTIVE
Here, we have performed a comprehensive longitudinal analysis of the systemic innate immune cell repertoire during the course of AIT.
METHODS
Patients with allergy received standard preseasonal subcutaneous AIT with allergoids to birch and/or grass. Healthy controls were monitored without any intervention. Flow cytometry of innate lymphoid cell (ILC), natural killer cell, monocyte cell, and dendritic cell (DC) subsets was performed at baseline, 3 months (birch season), 6 months (grass seasons), and 12 months after the therapy in patients or at similar seasonal time points in controls. Additional analyses were performed in the third-year birch and grass season.
RESULTS
We observed a durable decrease in group 2 ILCs and an increase of group 1 ILCs after AIT, with dynamic changes in their composition. We found that an expansion of CD127
CONCLUSION
AIT induces changes in the composition and heterogeneity of circulating innate immune cells and brings them to the level observed in healthy individuals. Monitoring of ILCs, monocytes, and DCs during AIT might serve as a novel biomarker strategy.

Identifiants

pubmed: 33039478
pii: S0091-6749(20)31396-8
doi: 10.1016/j.jaci.2020.08.042
pii:
doi:

Types de publication

Controlled Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1865-1877

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Andrzej Eljaszewicz (A)

Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.

Fiorella Ruchti (F)

Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland.

Urszula Radzikowska (U)

Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.

Anna Globinska (A)

Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland.

Tadech Boonpiyathad (T)

Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland; Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand; Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Anna Gschwend (A)

University Clinic for Rheumatology, Immunology and Allergology, Insel Hospital, University Hospital Bern, Bern, Switzerland.

Hideaki Morita (H)

Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland; Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.

Arthur Helbling (A)

University Clinic for Rheumatology, Immunology and Allergology, Insel Hospital, University Hospital Bern, Bern, Switzerland.

Stefania Arasi (S)

Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Pediatric Allergology Unit, Department of Pediatric Medicine, Bambino Gesù Children's Research Hospital (IRCCS), Rome, Italy.

Helga Kahlert (H)

Allergopharma GmbH & Co KG, Reinbek, Germany.

Nadine Berek (N)

Allergopharma GmbH & Co KG, Reinbek, Germany.

Andreas Nandy (A)

Allergopharma GmbH & Co KG, Reinbek, Germany.

Mübeccel Akdis (M)

Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.

Christoph Willers (C)

Allergopharma GmbH & Co KG, Reinbek, Germany.

Marcin Moniuszko (M)

Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland; Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.

Cezmi A Akdis (CA)

Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland.

Milena Sokolowska (M)

Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland. Electronic address: milena.sokolowska@siaf.uzh.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH